


**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

**Listing of Claims**

Claim 1-12. (Cancelled)

Claim 13. (Currently Amended) A compound of formula (I')



~~the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms or an N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof~~ wherein

R<sup>1</sup> and R<sup>2</sup> each independently represents hydrogen, C<sub>1-4</sub>alkyl, NR<sup>9</sup>R<sup>10</sup>, C<sub>1-4</sub>alkyloxy or Het<sup>3</sup>-O-C<sub>1-4</sub>alkyl; or

R<sup>1</sup> and R<sup>2</sup> taken together with the carbon atom with which they are attached from a C<sub>3-6</sub>cycloalkyl;

R<sup>4</sup> represents hydrogen, C<sub>1-4</sub>alkyl, or C<sub>2-4</sub>alkenyl;

U represents C<sub>1-4</sub>alkyloxy, phenyl, halo, oxo, carbonyl or hydroxyl;

R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>1-4</sub>alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C<sub>1-4</sub>alkyl, and C<sub>1-4</sub>alkyloxy or R<sup>5</sup> and R<sup>6</sup> each independently represent C<sub>1-4</sub>alkyl substituted with phenyl;

R<sup>7</sup> and R<sup>8</sup> are each independently selected from hydrogen or C<sub>1-4</sub>alkyl;

$R^9$  and  $R^{10}$  are each independently selected from hydrogen,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyloxycarbonyl;

$R^{11}$  and  $R^{12}$  are each independently selected from hydrogen, halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkyloxy, hydroxy, nitro,  $Het^4$ , phenyl, phenoxy,  $C_{1-4}$ alkyloxycarbonyl, hydroxycarbonyl,  $NR^5R^6$ ,  $C_{1-4}$ alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl,  $Het^2$  and  $NR^7R^8$ ,  $C_{2-4}$ alkenyl substituted with one substituent selected from phenyl- $C_{1-4}$ alkyl-oxycarbonyl,  $C_{1-4}$ alkyloxycarbonyl, hydroxycarbonyl,  $Het^5$ -carbonyl, and  $C_{1-4}$ alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, trimethylamine, amine, cyano,  $Het^6$ ,  $Het^7$ -carbonyl,  $C_{1-4}$ alkyloxycarbonyl or hydroxycarbonyl;

$Het^4$  represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

$Het^2$  represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said  $Het^2$  optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyloxy;

$Het^3$  represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

$Het^4$  represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said  $Het^4$  optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyloxy;

$Het^5$  represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said  $Het^5$  optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyloxy;

Het<sup>6</sup> represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het<sup>6</sup> optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy; and

Het<sup>7</sup> represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het<sup>7</sup> optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyloxy.

Claim 14-22. (Cancelled)

Claim 23. (Previously presented) A compound according to claim 13, wherein R<sup>1</sup> and R<sup>2</sup> each independently represents hydrogen, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>alkyloxy.

Claim 24. (Previously presented) A compound according to claim 13, wherein R<sup>1</sup> and R<sup>2</sup> each independently represents methyl or methoxy.

Claim 25. (Previously presented) A compound according to claim 13, wherein R<sup>1</sup> and R<sup>2</sup> taken together with the carbon atom with which they are attached form cyclopropyl or cyclobutyl.

Claim 26. (Previously presented) A compound according to claim 13, wherein R<sup>4</sup> represents hydrogen.

Claim 27. (Previously presented) A compound according to claim 13, wherein U represents hydroxy or halo.

Claim 28. (Currently Amended) A compound according to claim 13, wherein Het<sup>5</sup> represents a monocyclic heterocycle selected from piperazinyl or morpholinyl;.

Claim 29. (Previously presented) A compound according to claim 13, wherein Het<sup>7</sup> represents a monocyclic heterocycle selected from piperazinyl or morpholinyl.

Claim 30. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 13.

Claim 31. (Cancelled)

Claim 32. (Currently Amended) A compound according to claim 13, wherein the compound is selected from:

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-methyl-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-methoxy-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-hydroxy-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3,5-dimethyl-benzeneacetamide);

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-(carboxymethoxy)-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-[2-(4-morpholiny)ethoxy]-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-fluorotricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-benzeneacetamide;

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-benzeneacetamide;

(1 $\alpha$ ,2 $\alpha$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-benzeneacetamide;

3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid; and


4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid; and

~~tert butyl 4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate; or a N-oxide, a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof.~~

Claim 33. (New) A compound according to claim 13 wherein the compound is selected from

(1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethylbenzeneacetamide;  
 (1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-methylbenzeneacetamide; and  
 (1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)- $\alpha$ , $\alpha$ -dimethyl-3-methoxybenzeneacetamide; or a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

Claim 34. (New) A compound according to claim 13 wherein the compound is



or a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

Claim 35. (New) A compound according to claim 13 wherein R<sup>1</sup> and R<sup>2</sup> each represent C<sub>1-4</sub>alkyl.